Baseline characteristics and molecular testing of patients with IDH1-mutated cholangiocarcinoma: Initial results from the phase IIIb ProvIDHe study

被引：0
|
作者：
Rimassa, L. [1 ]
Bridgewater, J. A. [2 ]
Casadei-Gardini, A. [3 ]
Wilmink, H. [4 ]
Sim, H-W [5 ,6 ,7 ]
de Vos-Geelen, J. [8 ]
Mercade, T. Macarulla [9 ]
Malka, D. [10 ]
Gharbi, H. [11 ]
Robert, R. [11 ]
Sullivan, A. [12 ]
Vogel, A. [13 ]
机构：
[1] IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Rozzano, Italy
[2] UCL Canc Inst, Dept Med Oncol, Paul OGorman Bldg, London, England
[3] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst Hosp, Dept Oncol, Milan, Italy
[4] Locatie Acad Med Ctr AMC, Amsterdam Univ Med Ctr UMC, Med Oncol, Amsterdam, Netherlands
[5] Kinghorn Canc Ctr, Dept Med Oncol, Sydney, NSW, Australia
[6] Univ New South Wales, Fac Med & Hlth, Sydney, NSW, Australia
[7] Univ Sydney, NHMRC Clin Trials Ctr, Darlinghurst, NSW, Australia
[8] Maastricht Univ Med Ctr MUMC, Dept Internal Med, Div Med Oncol, Maastricht, Netherlands
[9] VHIO Vall dHebron Inst Oncol, Med Oncol Dept, Barcelona, Spain
[10] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[11] Servier, Global Med & Patient Affairs, Suresnes, France
[12] Servier Pharmaceut, Global Biometr, Boston, MA USA
[13] MHH, Hepatol Oncol, Hannover, Germany
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.159
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
138MO
引用
收藏
页码：S1457 / S1457
页数：1
相关论文
共 50 条
  • [31] Ivosidenib or Enasidenib Combined with Standard Induction Chemotherapy Is Well Tolerated and Active in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation: Initial Results from a Phase 1 Trial
    Stein, Eytan M.
    DiNardo, Courtney D.
    Mims, Alice S.
    Savona, Michael R.
    Pratz, Keith
    Stein, Anthony S.
    Fathi, Amir T.
    Stone, Richard M.
    Pollyea, Daniel A.
    Odenike, Olatoyosi
    Lowenberg, Bob
    Dohner, Hartmut
    Schiller, Gary J.
    Gupta, Ira V.
    Nabhan, Salah
    Zhang, Vickie
    Almon, Caroline
    Cooper, Michael
    Tallman, Martin S.
    BLOOD, 2017, 130
  • [32] Ivosidenib or Enasidenib Combined With Standard Induction Chemotherapy Is Well Tolerated and Active in Patients With Newly Diagnosed AML With an IDH1 or IDH2 Mutation: Initial Results From a Phase 1 Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) : 14 - 16
  • [33] Ivosidenib in treatment of patients with cholangiocarcinoma with IDH1 mutation - real-world data from a multicenter study
    Cybulska-Stopa, Bozena J.
    Kawecki, Maciej
    Szymanska, Patrycja
    Duszynski, Piotr
    Borysiewicz, Zuzanna
    Szwiec, Marek
    Gawinski, Cieszymierz
    Czamanska, Agnieszka
    Galinska, Bogumila
    Zukowska, Paulina
    Liberek, Hanna
    Chojnowska, Aleksandra
    Dziura, Robert
    Wyrwicz, Lucjan
    Krzakowski, Maciej
    ONCOLOGY IN CLINICAL PRACTICE, 2025,
  • [34] Immunogenicity of Rebif® New Formulation (interferon beta-1a) in patients with relapsing multiple sclerosis:: results from a phase IIIb study
    Giovannoni, G.
    Barbarash, O.
    Casset-Semanaz, F.
    King, J.
    Metz, L.
    Pardo, G.
    Simsarian, J.
    Sorensen, P. Soelberg
    Stubinski, B.
    JOURNAL OF NEUROLOGY, 2008, 255 : 80 - 80
  • [35] TQB3454 in mutant IDH1 advanced cholangiocarcinoma (CCA): Results of a phase I dose escalation and expansion study cohort
    Yuan, J.
    Zheng, Y.
    Xu, L.
    Xie, F.
    Gu, S.
    Li, Q.
    Zhang, J.
    Ba, Y.
    Huaxin, D.
    Yang, A.
    Li, J.
    Zhou, J.
    Shen, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S120 - S120
  • [36] Olutasidenib for Mutated IDH1 Acute Myeloid Leukemia: Final Five-Year Results From the Phase 2 Pivotal Cohort
    Cortes, Jorge
    Jonas, Brian A.
    Di Trapani, Francois
    Sheppard, Aaron
    Watts, Justin M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S318 - S318
  • [37] Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort
    Cortes, Jorge E.
    Jonas, Brian Andrew
    Watts, Justin M.
    Chao, Mwe Mwe
    De Botton, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group
    Sebert, Marie
    Cluzeau, Thomas
    Rauzy, Odile Beyne
    Bastard, Aspasia Stamatoulas
    Dimicoli-Salazar, Sophie
    Thepot, Sylvain
    Peterlin, Pierre
    Park, Sophie
    Gourin, Marie-Pierre
    Brehar, Oana
    Bally, Cecile
    Maury, Sebastien
    Fossard, Gaelle
    Selmi, Lamya Ait Si
    Chaffaut, Cendrne
    Clappier, Emmanuelle
    Itzykson, Raphael
    Chermat, Fatiha
    Chevret, Sylvie
    Fenaux, Pierre
    Ades, Lionel
    BLOOD, 2021, 138
  • [39] Pharmacokinetic/pharmacodynamic (PK/PD) profile of AG-120 in patients with IDH1-mutant cholangiocarcinoma from a phase 1 study of advanced solid tumors.
    Fan, Bin
    Goyal, Lipika
    Lowery, Maeve Aine
    Pandya, Shuchi Sumant
    Manyak, Erika
    Le, Kha
    Jiang, Liewen
    Auer, Julia
    Dai, David
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [40] Final Results of the Phase Ib/II Study Evaluating Enasidenib in Combination with Venetoclax in Patients with IDH2-Mutated Relapsed/Refractory Myeloid Malignancies
    Richard-Carpentier, Guillaume
    Gupta, Gopila
    Cameron, Charina
    Cathelin, Severine
    Bankar, Aniket
    Davidson, Marta Beata
    Gupta, Vikas
    Maze, Dawn C.
    Minden, Mark D.
    Murphy, Tracy
    Schimmer, Aaron D.
    Schuh, Andre C.
    Sibai, Hassan
    Yee, Karen
    DiNardo, Courtney D.
    Brandwein, Joseph
    McNamara, Caroline Jane
    Chan, Steven M.
    BLOOD, 2023, 142
12345